184 related articles for article (PubMed ID: 34000352)
21. The role of the androgen receptor in triple-negative breast cancer.
Shah PD; Gucalp A; Traina TA
Womens Health (Lond); 2013 Jul; 9(4):351-60. PubMed ID: 23826776
[TBL] [Abstract][Full Text] [Related]
22. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
23. The Role of the Androgen Receptor Signaling in Breast Malignancies.
Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
25. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
[TBL] [Abstract][Full Text] [Related]
26. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
28. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.
Chia KM; Liu J; Francis GD; Naderi A
Neoplasia; 2011 Feb; 13(2):154-66. PubMed ID: 21403841
[TBL] [Abstract][Full Text] [Related]
29. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
30. Consideration of breast cancer subtype in targeting the androgen receptor.
Venema CM; Bense RD; Steenbruggen TG; Nienhuis HH; Qiu SQ; van Kruchten M; Brown M; Tamimi RM; Hospers GAP; Schröder CP; Fehrmann RSN; de Vries EGE
Pharmacol Ther; 2019 Aug; 200():135-147. PubMed ID: 31077689
[TBL] [Abstract][Full Text] [Related]
31. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
32. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
[TBL] [Abstract][Full Text] [Related]
33. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
[TBL] [Abstract][Full Text] [Related]
34. Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia: A cross sectional study.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Karlsson C; Karlsson MG
PLoS One; 2020; 15(5):e0232519. PubMed ID: 32374753
[TBL] [Abstract][Full Text] [Related]
35. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.
Garay JP; Karakas B; Abukhdeir AM; Cosgrove DP; Gustin JP; Higgins MJ; Konishi H; Konishi Y; Lauring J; Mohseni M; Wang GM; Jelovac D; Weeraratna A; Sherman Baust CA; Morin PJ; Toubaji A; Meeker A; De Marzo AM; Lewis G; Subhawong A; Argani P; Park BH
Breast Cancer Res; 2012 Feb; 14(1):R27. PubMed ID: 22321971
[TBL] [Abstract][Full Text] [Related]
36. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
Biron E; Bédard F
J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
[TBL] [Abstract][Full Text] [Related]
37. Suppression of breast cancer cell growth by Her2-reduced AR serine 81 phosphorylation.
Huang PH; Wang HY; Huang CC; Lee YT; Yue CH; Chen MC; Lin H
Chin J Physiol; 2016 Aug; 59(4):232-9. PubMed ID: 27426262
[TBL] [Abstract][Full Text] [Related]
38. Targeting the androgen receptor in breast cancer.
Chia K; O'Brien M; Brown M; Lim E
Curr Oncol Rep; 2015 Feb; 17(2):4. PubMed ID: 25665553
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer.
Lyu S; Yu Q; Ying G; Wang S; Wang Y; Zhang J; Niu Y
Int J Oncol; 2014 Jan; 44(1):229-37. PubMed ID: 24172884
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]